10-Q: Fennec Pharmaceuticals Reports Q1 2025 Financial Results, Net Revenues Rise 18% YOY

Fennec Pharmaceuticals reports an 18% year-over-year increase in total net revenues for the first quarter of 2025, driven by growth in PEDMARK sales and strategic focus.

Summary

• Fennec Pharmaceuticals reported its Q1 2025 financial results, with total net revenues reaching $8.8 million, an 18% increase compared to $7.4 million in Q1 2024.
• The revenue growth is attributed to increased market penetration and access for PEDMARK, including expansion into the adolescent and young adult (AYA) population.
• Selling and marketing expenses decreased to $2.9 million in Q1 2025 from $5.2 million in Q1 2024, primarily due to the elimination of European pre-commercial activities following the Norgine partnership.
• General and administrative (G&A) expenses increased to $6.1 million in Q1 2025, mainly due to non-cash stock-based compensation.
• The company's cash and cash equivalents stood at $22.6 million as of March 31, 2025, a decrease from $26.6 million at the end of 2024, due to seasonal spending patterns.
• PEDMARQSI is now commercially available in Germany and the United Kingdom, with Norgine leading the commercialization efforts in Europe.
• Fennec's refined, targeted sales strategy and enhanced patient support services, including the revamped Fennec HEARS program, contributed to the positive momentum.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While revenue increased, the company still reported a net loss. The commercial launch in Europe and the revamped patient support program are positive developments, but the decrease in cash and the ongoing litigation introduce uncertainty.

Positives

• The company achieved an 18% increase in total net revenues year-over-year.
• PEDMARK sales are growing due to increased market penetration and expansion into the AYA population.
• The Norgine partnership has led to a decrease in selling and marketing expenses.
• PEDMARQSI is now commercially available in key European markets.
• The Fennec HEARS patient support program has been revamped to improve the patient and provider experience.
• Norgine announced the Scottish Medicines Consortium (SMC) acceptance of PEDMARQSI for use in Scotland.

Negatives

• Cash and cash equivalents decreased from $26.6 million to $22.6 million due to seasonal spending patterns.
• The company reported a net loss of $1.165 million for the quarter.

Risks

• The company's future performance is subject to risks and uncertainties inherent in the business, including regulatory changes, clinical trial outcomes, and market competition.
• Unforeseen global instability, including political instability, or instability from an outbreak of pandemic or contagious disease, such as the novel coronavirus (COVID-19), or surrounding the duration and severity of an outbreak.
• The company's ability to obtain necessary capital when needed on acceptable terms or at all.

Future Outlook

The company is focused on deepening relationships with key accounts, expanding adoption with new and existing customers, and driving value for patients, providers, and shareholders.

Management Comments

• In the first quarter, we sharpened our strategic focus and achieved sustainable growth across key PEDMARK accounts.
• Importantly, our Fennec HEARS patient support program has been newly revamped to ensure growth with a seamless, supportive experience for both providers and adolescent and young adult, or AYA, cancer patients at every step of the PEDMARK journey.
• Looking ahead, we are energized by the momentum that we are building and remain committed to executional excellence.
• We are deepening our relationships with key accounts and expanding adoption with new and existing customers.
• With this strong foundation and forward vision, we are confident in our ability to drive value for patients, providers, and shareholders.

Industry Context

Fennec Pharmaceuticals operates in the specialty pharmaceutical sector, focusing on treatments for rare conditions and unmet medical needs. The company's focus on pediatric cancer patients and the prevention of ototoxicity aligns with broader trends in oncology and supportive care.

Comparison to Industry Standards

• It is difficult to compare Fennec directly to industry standards due to its unique focus on preventing ototoxicity in pediatric cancer patients.
• However, the company's revenue growth and commercialization efforts can be benchmarked against other small to mid-sized pharmaceutical companies launching specialty products.
• Companies like BioCryst Pharmaceuticals and Eagle Pharmaceuticals, which focus on niche markets and specialty products, could be considered peers for comparison.
• The success of PEDMARQSI in Europe, commercialized by Norgine, can be compared to other European pharmaceutical launches in terms of market penetration and sales growth.

Legal Proceedings

• The company is involved in ongoing litigation with CIPLA regarding patents related to PEDMARK.

Stakeholder Impact

• The company's performance impacts shareholders, patients, healthcare providers, and employees.
• Positive developments, such as increased revenue and commercial expansion, benefit shareholders and improve access to treatment for patients.
• The revamped patient support program aims to improve the experience for both providers and patients.

Next Steps

• Fennec will be exhibiting at the ASCO Annual Meeting at Booth #37119, from May 30 June 3, 2025, in Chicago, IL.
• Fennec would like to invite shareholders to attend its Annual General Meeting on Tuesday, June 3, 2025 at 10:00 a.m. ET, which will be held in person in the Chairman Room at the NY Lotte Palace hotel located at 455 Madison Avenue, New York, NY 10022, or online by visiting www.virtualshareholdermeeting.com/FENC2025.
• Fennec will be participating in the upcoming HCW 3rd Annual BioConnect Conference, held in partnership with Nasdaq in NYC, on Tuesday, May 20, 2025.
• Fennec will be participating in the 22nd Annual Craig-Hallum Institutional Investor Conference being held in Minneapolis, MN on Wednesday, May 28, 2025.

Key Dates

Keywords

PEDMARK, PEDMARQSI, Fennec Pharmaceuticals, Ototoxicity, Revenue, Financial Results, Norgine, AYA population, Commercial Launch